Fig. 4

Effect of previous immune checkpoint inhibitor (ICI) administration on COVID-19 prognosis in patients with lung cancer. Patients were categorized into four groups: within 90 days from last ICI administration to COVID-19 diagnosis, 91–180 days, > 180 days, and non-ICI group, and the mortality rate for each group is indicated